Trillium Adds $1M for Clinical Trials
Biopharmaceutical company Trillium Therapeutics Inc. has closed on $1 million in equity financing from a new, undisclosed investor. The funds will help Trillium support clinical trials for a treatment for interstitial cystitis, also known as bladder pain syndrome. Toronto-based Trillium has previously raised funding from investors including Vengrowth Private Equity Partners, Growthworks Capital and BDC Capital.
12 May 2011•3 mins read
